Opfolda (Miglustat)

Miglustat, the active ingredient in Opfolda, is a iminosugar glucosylceramide synthase inhibitor presented as a oral tablet for oral use. It is used in the management of certain rare metabolic disorders, specifically in adult and paediatric patients with confirmed glycosylation defects. GNH USA supplies Opfolda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Opfolda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Opfolda (miguel miglustat) acts on the glycosphingolipid biosynthesis pathway and is prescribed for several rare disorders. - Type 1 Gaucher disease: improves clinical symptoms and reduces organ size when enzyme‑replacement therapy is insufficient. - Niemann‑Pick type C disease (NPC): slows disease progression and helps maintain neurological function in affected individuals. - Pompe disease (early onset) – used as adjunct therapy to enhance glycogen clearance in patients who cannot receive enzyme replacement.

Miglustat may cause a range of adverse reactions, most of which are mild and manageable.

Common Side Effects: - Diarrhea: watery, often mild to moderate. - Nausea: occasional upset stomach. - Weight loss: gradual reduction in body weight. - Flatulence: increased intestinal gas. - Abdominal pain: cramping or discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe hypersensitivity: rash, itching, swelling, or difficulty breathing. - Liver enzyme elevation: increased ALT/AST levels. - Peripheral neuropathy: tingling or numbness in extremities. - Mood changes: depression or anxiety. - Blood cell abnormalities: low white blood cells or platelets.

Before ​      ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​    ​ ​ ​​ ​ ​​ ​​ ​ ​ ​ ​ ​​ ​​ ​ ​​ ​​ ​​​  ​​ ​ ​​ ​​ ​ ​​ ​​ -  ​  "); -  ");   -  t  t t t t t t". -  t. """"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""". -  """

The      """ """ " """ """ "" "" " " "" " "" " "